Keryx Pharma: Brean Says Today Undermines Bear Points On Co., Lowers PT To $18 From $22, Maintains Buy

Loading...
Loading...
Brean makes clear that a possible short squeeze is not lost on the firm, should exacerbate performance into positive catalysts.
Market News and Data brought to you by Benzinga APIs
Posted In: Analyst ColorNewsPrice TargetAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...